---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-038624"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2026-10-05T20:16:48+00:00"
generated_at: "2026-10-12T14:51:12.762584+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools to sell Microfluidics business to ARCHIMED; close expected in ~30 days

## Summary
- Standard BioTools (NASDAQ: LAB) signed a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm; closing expected in approximately 30 days.
- No purchase price, revenue multiple, or other financial terms for the Microfluidics sale were disclosed in the press release.
- CEO Michael Egholm called it 'a strong outcome for our employees and our customers' and 'another important step in the strategic actions we laid out' for shareholders.
- Microfluidics will keep operating as part of Standard BioTools until closing; the deal is subject to customary closing conditions.
- Separately pending: a merger with Treeline Biosciences (Form S-4 preliminary proxy filed July 20, 2026) and a sale of the Mass Cytometry unit to Element Biosystems.

## SEC filing metadata
- accession: 0001140361-26-038624
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2026-10-05T20:16:48+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000114036126038624/0001140361-26-038624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000114036126038624/ef20083295_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-038624
- JSON: https://secwatch.observer/filing/0001140361-26-038624.json
- Plain text: https://secwatch.observer/filing/0001140361-26-038624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.